These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19456275)

  • 21. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.
    Favoni RE; Alama A
    Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.
    El-Nikhely N; Larzabal L; Seeger W; Calvo A; Savai R
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1107-22. PubMed ID: 22667993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.
    Sato T; Gotoh N
    Expert Opin Ther Targets; 2009 Jun; 13(6):689-700. PubMed ID: 19456272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic cancer: from molecular pathogenesis to targeted therapy.
    Strimpakos A; Saif MW; Syrigos KN
    Cancer Metastasis Rev; 2008 Sep; 27(3):495-522. PubMed ID: 18427734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal transduction pathways as novel therapy targets in lung cancer.
    Reinmuth N; Mesters RM; Bieker R; Hoffknecht P; Berdel WE; Thomas M
    Lung Cancer; 2004 Aug; 45 Suppl 2():S177-86. PubMed ID: 15552798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potential agent for treating non-small cell lung cancer.
    Ou JS; Huang DD; Ou ZJ
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):985-6. PubMed ID: 18782201
    [No Abstract]   [Full Text] [Related]  

  • 27. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for lung cancer: the state of the art in 2009.
    Higgins MJ; Ettinger DS
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1365-78. PubMed ID: 19827996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
    Jalal SI; Ademuyiwa FO; Hanna NH
    Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone acetyltransferase inhibitors and preclinical studies.
    Manzo F; Tambaro FP; Mai A; Altucci L
    Expert Opin Ther Pat; 2009 Jun; 19(6):761-74. PubMed ID: 19473103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
    Cho Y; Park MJ; Park M; Min SS; Yee J; Kim C; Han MS; Han SH
    Respirology; 2009 Aug; 14(6):850-8. PubMed ID: 19703066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted drug delivery strategies to treat lung metastasis.
    Bar J; Herbst RS; Onn A
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1003-16. PubMed ID: 19663628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy].
    Brückl WM; Lampert S; Zirlik S; Hahn EG; Wiest GH
    Pneumologie; 2008 Jan; 62(1):23-30. PubMed ID: 17948174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road.
    Gridelli C
    Curr Opin Oncol; 2008 Mar; 20(2):145-7. PubMed ID: 18300763
    [No Abstract]   [Full Text] [Related]  

  • 37. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of radiotherapy and chemotherapy in locally advanced NSCLC.
    Kepka L; Sprawka A; Casas F; Abdel-Wahab S; Agarwal JP; Jeremic B
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1389-403. PubMed ID: 19827998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
    Cakir M; Grossman AB
    Expert Opin Ther Targets; 2009 Sep; 13(9):1121-34. PubMed ID: 19637976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.